UK's IXICO expects FY26 revenue to rise on neuroimaging demand

IXICO

Tue 07:12

Overview
UK neuroscience imaging firm's FY26 revenue expected to rise 28% yr/yr to £8.3 mln
Year-end order book increased to £16.0 mln, supporting future revenue visibility
Year-end cash rose after £9.4 mln capital raise completed in April 2026

Outlook
Company expects FY26 revenue of £8.3 mln, exceeding previous guidance of £8.0 mln
IXICO says FY26 EBITDA loss expected to improve versus previous guidance of £1.7 mln loss
Company enters FY27 with strong order book and expects continued growth momentum

Result Drivers
NEUROSCIENCE DEMAND - Co said revenue growth was driven by increased demand for specialist neuroimaging and biomarker analytics capabilities
NEW CLINICAL TRIALS - Co said it secured new clinical trial programmes and expanded relationships with existing customers
STRATEGY EXECUTION - CEO said disciplined execution of Innovate, Lead, Scale strategy drove strong demand for neuroimaging capabilities

Company press release: ID:nRST5738Za

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
 
GBP 8.30 mln
 
FY Order Backlog
 
GBP 16 mln
 

Reuters Recommended Reads
Oct 19 - UK risks becoming 'AI customer' rather than creator, advisers warn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)